Eye care pharmaceutical firm Alcon has moved into its new S$200 million manufacturing plant in Tuas Biomedical Park in Singapore.
The move will help the firm boost its capacity to meet the growing eye care needs in Asia.
The new 330,000 square foot plant will manufacture products for patients with dry eyes, glaucoma, allergies and bacterial infections in the eye.
US-based Alcon is the second largest division of the Novartis Group.
This is Novartis’ third manufacturing plant and Alcon’s second facility in Singapore.
In 2005, Alcon opened a contact lens manufacturing facility in the Tuas Biomedical Park.
Country President for Novartis Singapore and Head of Group Country Management, Christopher Snook, said: “Singapore’s robust biomedical presence, and the highly skilled and knowledgeable workforce made it easy to choose Singapore for our new site.”
“Asia is a very fast growth market and region for us and it is right therefore that we produce products nearby where our customer base is. That’s why this facility, our third factory in Singapore, is a specialist eye care facility and this is on top of the other facilities, pharmaceutical manufacturing and contact lens factories that we have in Singapore already,” he added.
Source : Channel News Asia | April 14, 2014